Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00205-0
Affiliations:
21
Authors:
67
Go to article
Institutions Authors Share
non-affiliated author contributions, United Kingdom (UK)
41.050000
41.050000
41.050000
41.050000
41.050000
 0.61
The Institute of Cancer Research (ICR), United Kingdom (UK)
8.050000
 0.12
The Royal Marsden NHS Foundation Trust, United Kingdom (UK)
1.550000
 0.02
Sunnybrook Health Sciences Centre, U of T, Canada
1.050000
 0.02
University Hospitals of Leicester NHS Trust (UHL), United Kingdom (UK)
1.050000
 0.02
The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, United Kingdom (UK)
1.050000
 0.02
Queen's University Belfast (QUB), United Kingdom (UK)
1.050000
 0.02
The Clatterbridge Cancer Centre NHS Foundation Trust, United Kingdom (UK)
1.050000
 0.02
Cardiff University, United Kingdom (UK)
1.050000
 0.02
Auckland City Hospital (ACH), New Zealand
1.050000
 0.02
Beatson West of Scotland Cancer Centre (BWoSCC), United Kingdom (UK)
1.050000
 0.02
University Hospitals Coventry and Warwickshire NHS Trust, United Kingdom (UK)
1.050000
 0.02
London Health Sciences Centre (LHSC), Canada
1.050000
 0.02
Cambridge University Hospitals NHS Foundation Trust, United Kingdom (UK)
1.050000
 0.02
UCL, United Kingdom (UK)
1.050000
 0.02
Bon Secours Health System, Ireland
1.050000
 0.02
Mount Vernon Cancer Centre, United Kingdom (UK)
1.050000
 0.02
Cancer Trials Ireland, Ireland
0.550000
 0.01
St. Luke's Hospital, Ireland
0.550000
 0.01
The Radiotherapy Trials Quality Assurance (RTTQA) Group, United Kingdom (UK)
0.550000
 0.01
Interested in Oncology and Carcinogenesis?